Find Technologies

Request Information

Bersavine-Derived c-Myc Targeting Compounds as a Broad Anti-Cancer Therapy

Tech ID: 34144 / UC Case 2025-682-0

BACKGROUND

A major driver in a number of cancers is the dysregulation and overexpression of c-Myc1. c-Myc is a crucial factor in cell metabolism, growth, division, and even programmed cell death, and its abnormal activity is found in many cancers, including various lymphomas. Because c-Myc has long been viewed as an "undruggable" oncogene, effective therapeutic strategies remain limited; for this reason, research aimed at finding viable ways to target c-Myc is both necessary and in high demand.

BRIEF DESCRIPTION

Professor Kevin Kou and his team at the University of California, Riverside, in collaboration with Professor Wendong Huang's lab at City of Hope, have developed a new method for synthesizing modified versions of bersavine. Using this method, several novel bersavine compounds were synthesized. When these new compounds were tested against lymphoma cells, powerful anti-cancer effects were demonstrated. Notably, these newly synthesized analogs are more effective at inhibiting cell growth than the naturally occurring bersavine.



SUGGESTED USES

► A new synthetic route to enable the creation of new, potent bersavine derivatives for the treatment of cancer.

Permalink

CONTACT Grace Yee grace.yee@ucr.edu tel: 951-827-2212.

OTHER INFORMATION

KEYWORDS CaMKII, CaMKII?, lymphoma, bersavine

CATEGORIZED AS
Medical

Disease: Cancer

RELATED CASES 2025-682-0

RELATED MATERIALS

▶ Lujan, B., Zhang, M., Cao, Y., Kacker, A., Mai, L., Wu, S., Alexander, T., Huang, W., & Kou, K. G. (2025). Semisynthesis of Bersavine and Berbamine derivatives that target the camkii?:CMYC axis for lymphoma therapy. Organic & Biomolecular Chemistry, 23(18), 4403–4408. https://doi.org/10.1039/d5ob00310e - 04/09/2025

University of California, Riverside Office of Technology Commercialization 200 University Office Building, Riverside,CA 92521 otc@ucr.edu https://research.ucr.edu/

Terms of use | Privacy Notice | © 2025, The Regents of the University of California